GeoVax Labs (NASDAQ:GOVX) Announces Quarterly Earnings Results

GeoVax Labs (NASDAQ:GOVX) released its earnings results on Thursday. The company reported ($2.62) EPS for the quarter, beating the consensus estimate of ($3.50) by $0.88, FiscalAI reports.

GeoVax Labs Trading Down 3.1%

Shares of GOVX traded down $0.04 on Thursday, reaching $1.26. 125,676 shares of the company’s stock were exchanged, compared to its average volume of 213,543. The stock has a market capitalization of $3.65 million, a P/E ratio of -0.04 and a beta of 3.36. The business has a 50 day moving average price of $1.42 and a two-hundred day moving average price of $4.84. GeoVax Labs has a 12 month low of $0.96 and a 12 month high of $34.75.

Institutional Investors Weigh In On GeoVax Labs

A number of institutional investors and hedge funds have recently modified their holdings of GOVX. Jane Street Group LLC bought a new stake in shares of GeoVax Labs during the first quarter worth approximately $27,000. Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the third quarter worth approximately $253,000. Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs in the 4th quarter valued at about $104,000. Finally, HRT Financial LP bought a new stake in shares of GeoVax Labs in the 4th quarter valued at about $31,000. 6.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

GOVX has been the topic of several research reports. Wall Street Zen lowered GeoVax Labs to a “strong sell” rating in a research note on Saturday, January 17th. D. Boral Capital reaffirmed a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.